Radium-223, An Alpha Emitter Treatment for Advanced Prostate Cancer Called A Breakthrough Treatment

In an interview about radium 223 with Medscape Medical News, Dr. Vapiwala pointed out that radium-223 is the first alpha-emitter to reach the market, and described it as a "breakthrough for radiopharmaceuticals" and "another breakthrough for prostate cancer," as it joins several other agents that have recently been approved for this disease. She characterized the [...]

Evidence That Vitamin D3 Levels Effect Survival in Men with Stage IV Advanced Prostate Cancer

Conversations among survivors and evidence in the literature suggests that there is a positive association between serum 25-hydroxyvitamin D [25(OH)D] (vitamin D3) and survival in certain types of cancer, including advanced prostate cancer. Researchers from the Cancer Treatment Centers of America investigated the relationship between survival advantage and vitamin D3 levels in [...]

Efficacy and Safety of Enzalutamide (Xtandi) Monotherapy in Hormone-Naive Prostate Cancer (HNPC)

Xtandi is often referred to as a “super bicalutamide (Casodex).” Casodex functions as a androgen blockade, which deters testosterone from being able to interact with the prostate cancer cell and feed the growth of the cancer. There are some oncologists in the United States and the standard hormone treatment in Europe often utilizes Casodex as [...]

Sorting Out the Recent Negative News about the Role of Omega 3 Fatty Acids in the Diet & Its Relationship to Prostate Cancer

The recent news is unavoidable, Omega-3 Fatty Acids, usually used by men with heart ailments and prostate cancer is tied to a 71% increase of developing prostate cancer and that the cancer is often an aggressive prostate cancer! A prospective study by scientists at Fred Hutchinson Cancer Research Center has confirmed the link between high [...]

Salvage Radio Therapy Extends Life Without Regard to PSA Doubling Time

Researchers at Duke University observed a survival benefit for men who had salvage radiation therapy (RT) for prostate-specific antigen (PSA) failure after radical prostatectomy (RP) in the men who experience a rapid rises in PSA doubling time (DT,< 6 months). They then asked whether such a benefit also exits in men with a protracted PSA [...]

Go to Top